Nurix Therapeutics (NRIX) Retained Earnings (2019 - 2025)
Historic Retained Earnings for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to -$1.0 billion.
- Nurix Therapeutics' Retained Earnings fell 3579.7% to -$1.0 billion in Q4 2025 from the same period last year, while for Nov 2025 it was -$1.0 billion, marking a year-over-year decrease of 3579.7%. This contributed to the annual value of -$1.0 billion for FY2025, which is 3579.7% down from last year.
- Per Nurix Therapeutics' latest filing, its Retained Earnings stood at -$1.0 billion for Q4 2025, which was down 3579.7% from -$925.0 million recorded in Q3 2025.
- Nurix Therapeutics' 5-year Retained Earnings high stood at -$128.0 million for Q1 2021, and its period low was -$1.0 billion during Q4 2025.
- For the 5-year period, Nurix Therapeutics' Retained Earnings averaged around -$508.5 million, with its median value being -$484.8 million (2023).
- In the last 5 years, Nurix Therapeutics' Retained Earnings crashed by 11865.75% in 2021 and then plummeted by 3274.16% in 2024.
- Over the past 5 years, Nurix Therapeutics' Retained Earnings (Quarter) stood at -$220.9 million in 2021, then crashed by 81.65% to -$401.3 million in 2022, then tumbled by 35.87% to -$545.2 million in 2023, then tumbled by 35.5% to -$738.8 million in 2024, then tumbled by 35.8% to -$1.0 billion in 2025.
- Its Retained Earnings was -$1.0 billion in Q4 2025, compared to -$925.0 million in Q3 2025 and -$838.6 million in Q2 2025.